Randomized clinical trial comparing the efficacy and safety of treatment with the once‐weekly dipeptidyl peptidase‐4 (DPP‐4) inhibitor omarigliptin or the once‐daily DPP‐4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy

AIM: To compare the efficacy and safety of the once‐weekly oral dipeptidyl peptidase‐4 (DPP‐4) inhibitor omarigliptin or once‐daily DPP‐4 inhibitor sitagliptin in patients with type 2 diabetes (T2DM) and inadequate glycaemic control on metformin. MATERIALS AND METHODS: Patients with T2DM with a glyc...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldenberg, Ronald, Gantz, Ira, Andryuk, Paula J., O'Neill, Edward A., Kaufman, Keith D., Lai, Eseng, Wang, Yin Na, Suryawanshi, Shailaja, Engel, Samuel S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347923/
https://www.ncbi.nlm.nih.gov/pubmed/28093853
http://dx.doi.org/10.1111/dom.12832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347923/
https://www.ncbi.nlm.nih.gov/pubmed/28093853
http://dx.doi.org/10.1111/dom.12832

Ejemplares similares